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Abstract
The goal of this study is to develop small molecule inhibitors of DHPS for the treatment of a variety of
infectious diseases. According to the World Health Organization (WHO), infectious diseases kill more
than 13 million people worldwide every year making it the second leading cause of death behind
cardiovascular disease. The sulfonamide class of drugs has been in use since the 1930’s to treat many
infectious agents and act by targeting the enzyme dihydropteroate synthase (DHPS) of the prokaryotic
and lower eukaryotic folate pathway.
DHPS is an ideal drug target because humans do not synthesize folate de novo and is a well validated
system. However, the emergence of bacterial resistance has limited the efficacy of sulfonamides, and an
increasing trend in drug resistance has heightened the need for development of new therapeutics.
Although drug resistance has severely limited the clinical use of sulfonamides, the folate pathway, and
DHPS in particular, remain an ideal target for therapeutic development. This is due to the fact that DHPS
accommodates two substrates, para-aminobenzoic acid (pABA) and 6-hydroxymethyl-7,8-dihydropterinpyrophosphate (DHPPP), which bind to separate and distinct regions of the protein. Sulfonamides act by
binding the pABA pocket composed largely of dynamic loop regions which fold in upon substrate binding
to complete the active site. In contrast, the pterin pocket is a highly conserved, rigid binding site, and is
predicted to be more suitable for the development of small molecule inhibitors. Therefore, we propose
targeting the pterin binding site as a means of developing novel small molecule inhibitors of DHPS.
The advantages of this method are that pterin binds to a distinct region of DHPS separate from the pABA
binding site and removed from areas known to accommodate sulfonamide resistance. In addition, it
provides a novel approach to exploit a well validated drug target. We hypothesize that pterin-based
compounds will provide a new class of antibiotics that will overcome the problems of drug resistance and
provide novel therapeutics for a broad spectrum of infectious diseases.
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Abstract
The goal of this study is to develop small molecule inhibitors of DHPS for the
treatment of a variety of infectious diseases. According to the World Health Organization
(WHO), infectious diseases kill more than 13 million people worldwide every year
making it the second leading cause of death behind cardiovascular disease. The
sulfonamide class of drugs has been in use since the 1930’s to treat many infectious
agents and act by targeting the enzyme dihydropteroate synthase (DHPS) of the
prokaryotic and lower eukaryotic folate pathway.
DHPS is an ideal drug target because humans do not synthesize folate de novo
and is a well validated system. However, the emergence of bacterial resistance has
limited the efficacy of sulfonamides, and an increasing trend in drug resistance has
heightened the need for development of new therapeutics. Although drug resistance has
severely limited the clinical use of sulfonamides, the folate pathway, and DHPS in
particular, remain an ideal target for therapeutic development. This is due to the fact that
DHPS accommodates two substrates, para-aminobenzoic acid (pABA) and 6hydroxymethyl-7,8-dihydropterin-pyrophosphate (DHPPP), which bind to separate and
distinct regions of the protein. Sulfonamides act by binding the pABA pocket composed
largely of dynamic loop regions which fold in upon substrate binding to complete the
active site. In contrast, the pterin pocket is a highly conserved, rigid binding site, and is
predicted to be more suitable for the development of small molecule inhibitors.
Therefore, we propose targeting the pterin binding site as a means of developing novel
small molecule inhibitors of DHPS.
The advantages of this method are that pterin binds to a distinct region of DHPS
separate from the pABA binding site and removed from areas known to accommodate
sulfonamide resistance. In addition, it provides a novel approach to exploit a well
validated drug target. We hypothesize that pterin-based compounds will provide a new
class of antibiotics that will overcome the problems of drug resistance and provide novel
therapeutics for a broad spectrum of infectious diseases.
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Chapter 1: Introduction

Discovery of Sulfonamides
Sulfonamides were the first antimicrobial to be developed and their discovery laid
the foundation for many of the concepts and techniques used in modern drug discovery.
They were first discovered in 1932 by German scientist Gerhard Domagk. Working at the
I. G. Farbenindustrie on methods for staining pathogenic bacteria, Domagk observed that
an azo dye, Prontosil Rubrum, protected mice and rabbits against lethal doses of
staphylococci and streptococci, but was ineffective in cell cultures (Domogk, 1935). It
was later shown that the azo linkage of Prontosil Rubrum is metabolized by liver
enzymes to yield the active drug, sulfanilamide, and developed the concept of
bioactivation (Domogk, 1935) (Figure 1.1A). During the 1940’s, it was shown that
addition of para-aminobenzoic acid (pABA) to bacteria colonies could overcome drug
activity indicating that sulfonamides target the folate biosynthetic pathway (Brown,
1962). However, it was nearly three decades before Richey and Brown (Richey & Brown,
1969) demonstrated that sulfanilamide was a potent inhibitor of the folate enzyme
dihydropteroate synthase (DHPS) by purifying DHPS and performing in vitro analysis
(Brown, 1962).
DHPS catalyzes the condensation of para-aminobenzoic acid (pABA) and 6hydroxymethyl-7,8-dihydropterin-pyrophosphate (DHPPP) to form dihydropteroate, a
precursor of tetrahydrofolate which is used for DNA synthesis. The sulfonamide group of
sulfanilamide mimics the carboxyl functional group of pABA. Since sulfur is a more
electron rich element than carbon, the pKa of the molecule is increased to 10.4 as
compared to the pABA pKa of ~6.5. Therefore, second generation sulfonamides were
optimized with the addition of an electron withdrawing ring to lower the pKa making
them more efficient inhibitors of DHPS (Figure 1.1B).

A

B

Figure 1.1: Structure of Sulfonamides. A. Schematic representation of prontosil
metabolism by liver enzymes. B. Structure of the first and second generation
sulfonamides.
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Sulfonamides and the Treatment of Infectious Diseases
After their discovery in the early 1930’s, sulfa drugs became widely used and
served as a first line treatment against bacterial infections. Pharmaceutical companies
aggressively researched sulfonamides at the outbreak of the Second World War to
produce potent inhibitors of infectious agents to prevent wound infection. Prisoners at the
Ravensbrueck concentration camp were used as test subjects by the German army to
investigate the effectiveness of sulfonamides in preventing infections in open wounds
(U.S. Holocaust Memorial Museum). As a result of these studies, soldiers were issued
first aid kits containing sulfa powder which they were told apply to any open wounds
incurred on the battlefield.
Sulfa powder, also known as co-trimoxazole, is a combination of
sulfamethoxazole (SMX) and trimethoprim (TMP). TMP targets the enzyme
dihydrofolate reductase (DHFR) which catalyzes the reduction of dihydrofolate to
tetrahydrofolate in the folate pathway downstream of DHPS. Currently, sulfonamides are
still an effect treatment for a variety of infectious disease (Table 1.1), but the increase in
drug resistance has limited their clinical use.
Development of Antibiotic Resistance
Historically, sulfonamides have been used as first line treatments for several
infectious diseases including malaria, leprosy, pneumonia, E. coli, and S. aureus.
However, antibiotic resistance has emerged as an important factor that severely limits the
clinical use of sulfonamides (Sköld, 2000; 2001), and resistance mutations in clinical
isolates of many pathogenic organisms have been characterized (Table 1.2). The most
common mechanism of acquired resistance has been linked to mutations in the folP gene
which encodes for DHPS. The majority of these mutations are localized in Loops-1 and 2 which fold in upon substrate binding to complete the pABA/sulfonamide binding site,
and primarily affect inhibitor binding. Sulfonamide resistance does not always involve a
Table 1.1: Types of Sulfonamides and Therapeutic Uses.
Sulfonamides
Therapeutic Indications
trimethoprim-sulfamethoxazole Treatment and prophalaxis of pneumonia
First attack of urinary infection
pyrimethamine-sulfadiazine
Treatment and prophalaxis of cerebral toxoplasmosis
silver sulfacetamine
Prevention/ treatment of bacterial infection for burn
patients
sodium sulfacetamie
Conjunctivitis and related superficial ocular infections
sulfadoxine and sulfalene in
Chloroquine-resistant malaria
combination with quinine
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Table 1.2: Resistance Mutations from Clinical Isolates.
Organisms
E. coli
N. meningitides
P. cariii
M. leprea
P. carinii

Mutation Observed
Phe28Lue, Ile
Phe31Leu
Phe23Leu
Thr53Ile, Ala
Thr55Ala

Ser436Ala, Phe
Arg58-Pro59 duplication
Pro55Leu
Pro57Ser
Pro64Ser
Arg Insertion after Gly60
Ser61 duplication
His60Asp
Ile66-Glu67 duplication
Ile111Thr
Lys540Glu
Gly194Cys, Ser193N. meningitides Gly194
Duplication
P. falciparum Ala581Gly
P. falciparum Ala613Ser, Thr
Val248Gly
P. carinii
P. falciparum
S. pneumoniae
M. leprea
P. carinii
E. coli
S. pneumoniae
S. pneumoniae
P. carinii
S. pneumoniae
P. carinii
P. falciparum

Corresponding Ba Residue
Phe33
Phe33
Phe33
Thr67
Thr67

Structure
Loop 1
Loop 1
Loop 1
Loop 2
Loop 2

Thr67
Arg68-Pro69
Pro69
Pro69
Pro69
Gly70
Phe71
Ala72
Val74-Ser75
Ile122
Asn147

Loop 2
Loop 2
Loop 2
Loop 2
Loop 2
Loop 2
Loop 2
Loop 2
Loop 2
Loop 4
Loop 5

Gly188

Loop 6

Gly190
Gly224
Ile246

Loop 6
α7’
α7’
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single point mutation, but is often found to contain multiple alterations in the folP gene,
resulting in changes of up to 10% of the amino acid sequence as compared to sensitive
isolates (Radstom et al., 1992; Quarnstrom & Swedberg, 2000).
DHPS and the Folate Biosynthetic Pathway
DHPS is a key enzyme in the folate biosynthetic pathway which catalyzes the
condensation of 6-hydroxymethyl-7,8–dihydropterin-pyrophosphate (DHPPP) with paraaminobenzoic acid (pABA) in the production of the intermediate dihydropteroate (Figure
1.2). The pathway serves to generate the cofactor tetrahydrofolate, which is essential to
all organisms for the metabolic reactions that involve one-carbon transfer such as DNA
synthesis. Prokaryotes and some lower eukaryotes require these enzymes for folate
biosynthesis. However, higher eukaryotes utilize high affinity transport systems which
absorb folate from the gut in the form of folic acid (Matherly, 2001). Therefore, DHPS is
an ideal drug target because humans do not synthesize folate de novo and is a well
validated system. Chapter 4 of this thesis deals with our efforts to structurally
characterize the DHPS enzyme in complex with sulfonamide inhibitors to better
understand the structural determinants of sulfonamide resistance.
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Figure 1.2: Schematic Representation of Tetrahydrofolate Synthesis.
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Chapter 2: X-ray Crystallography

Introduction
X-ray crystallography is a method of determining the special arrangement of
atoms within a crystal lattice. Crystals described as regular arrays of atoms which are
able to scatter X-ray wave, primarily through the atom’s electrons. Using the angles and
intensities of the scattered beams, a three-dimensional model of the electrons within the
crystal can be obtained. From the electron density, the mean position of the atoms can be
determined as well as their chemical bonds. For this reason, x-ray crystal structures are
useful for shedding light on chemical interactions and processes and serve as a basis for
designing pharmaceuticals against diseases. Indeed, modern applications of x-ray
crystallography have led to the development of a new area of research known as
structure-based drug design. Structure-based drug design is a technique which utilizes
known molecular structures in conjunction with computational methods to allow a drug
molecule to be constructed within the biomolecule using knowledge of its structure and
the nature of its active site.
History
Crystals have been scientifically investigated since the 17th century when
Johannes Kepler hypothesized that the hexagonal symmetry of snowflakes was due to a
regular packing of water molecules (Kepler, 1611). After the 18th century, investigation
by Nicolas Steno (Steno, 1669) and Rene Just Hauy (Hauy, 1784) led to the conclusion
that crystals can be described by simple stacking patterns of ―blocks‖ of the same shape
and size. By the mid 19th century, William Hallowes Miller was able to identify crystal
faces by giving each face a unique label of three small integers known as the Miller
indices. These studies led to the idea that crystals are a regular three-dimensional array of
atoms and molecules in a single unit cell which is repeated indefinitely along three
principle directions. By the conclusion of the 19th century, a complete catalog of possible
crystal symmetries had been determined and would later be validated by X-ray
crystallography.
At the turn of the century, Wilhelm Conrad Rontgen discovered X-rays which
were quickly determined to be waves of electromagnetic radiation. However, X-rays are
composed of photons, introduced by Albert Einstein, and thus are not only waves of
electromagnetic radiation but also exhibit particle-like properties (Einstein, 1905). The
idea to use crystals as a gradient for X-rays arose a collaborative effort between Paul
Peter Ewald and Max von Laue. The team exposed a sphalerite crystal to an X-ray beam
and recorded the diffraction pattern onto a photographic plate. Once the plate was
developed, it revealed a large number of well-defined spots arranged in a pattern of
intersecting circles around the spot produced by the central beam (Ewald, 1962).
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From that point on X-ray crystallography boomed. The atomic structure of table
salt became the first to be solved in 1914 and proved the existence of ionic compounds
(Bragg, 1914; 1922). X-ray diffraction was a widely accepted technique in material
science, chemistry, mineralogy and metallurgy. Discovery after discovery was being
made to find new ways of utilizing and improving the principle methods of structure
determination. Soon, organic and biological molecules were being crystallized and
studied with the work of Dorothy Crowfoot Hodgkin as the premier crystallographer. In
1964, she was awarded the Nobel Prize in Chemistry for solving the structures of
cholesterol, vitamin B12, and penicillin. In the late 1950’s, the structure of sperm whale
myoglobin was solved by Max Perutz and Sir John Cowerdry Kendrew making it the first
protein structure to be determined via X-ray crystallography. Since then, thousands of
proteins, nucleic acids, and other biological molecules have been determined using this
technique.
Diffraction Theory
Understanding of how diffraction theory relates to crystal structure determination
begins by studying the work of William Lawrence Bragg. Bragg proposed a model in
which a given reflection is associated with a set of evenly spaced sheets running through
the crystal, usually passing through the centers of the atoms of the crystal lattice. The
orientation of a particular set of sheets is identified by its Miller indices (h, k, l), and let
their spacing be noted by a distance, d. Incoming X-rays are scattered in a mirror-like
fashion from each plane. The X-rays scattered from adjacent planes will combine
constructively when the angle θ between the plane and the X-ray results in a path-length
difference that is an integer multiple n of the X-ray wavelength λ. This concept is known
as constructive interference and can be represented by the formula below.

Therefore, diffraction only occurs at so called Bragg’s peaks. That is, for an ideal crystal,
the electron density is perfectly periodic and the Fourier transform, F(q), is zero except
when q belongs to the reciprocal lattice, that is, to a particular oscillation in the electron
density in the direction in which q points. The reciprocal of the reciprocal lattice
therefore is the original lattice of the crystal.
X-ray crystallography is used to determine the density of electrons f(r) throughout
a given crystal, where r represents the three-dimensional position vector within the
crystal. To do this, X-ray scattering is used to collect data about its Fourier transform,
F(q),

where the integral is summed over all possible values of q. The three-dimensional real
vector q represents a point in reciprocal space. Since the length of q corresponds to 2π
7

divided by the wavelength of the oscillation, the following formula for a Fourier
transform can be used:

where the integral is summed over all possible values of the position vector r within the
crystal.
The Fourier transform F(q) has two main components which must be accounted
for experimentally in order to calculate the electron density of a crystal lattice: a
magnitude |F(q)| and a phase φ(q) related by the equation,

The intensities of the reflections observed in X-ray diffraction are synonymous with the
magnitudes |F(q)| but give no information regarding the phases φ(q). To obtain the
phases, full sets of reflections are collected with known alterations to the scattering, and
combining the magnitudes and phases yields the full Fourier transform F(q), which may
be inverted to obtain the electron density f(r). Several methods are available for
determining phase information.
Ab initio phasing, also known as direct methods – Although this method is most
commonly used for small molecules, it been used successfully to solve the phase
problems for small proteins. If the resolution of the data is better than 1.4 Å
(140 pm), direct methods can be used to obtain phase information, by exploiting
known phase relationships between certain groups of reflections.
Molecular replacement – This method is often used if a structure exists of a
related structure, it can be used as a search model in molecular replacement to
determine the orientation and position of the molecules within the unit cell. The
phases obtained this way can be used to generate an electron density maps.
Anomalous X-ray scattering (MAD or SAD phasing) – the X-ray wavelength may
be scanned past an absorption edge of an atom, which changes the scattering in a
known way. By recording full sets of reflections at three different wavelengths
(far below, far above and in the middle of the absorption edge) one can solve for
the substructure of the anomalously diffracting atoms and thence the structure of
the whole molecule. The most popular method of incorporating anomalous
scattering atoms into proteins is to express the protein in a methionine auxotroph
(a host incapable of synthesising methionine) in a media rich in Selenomethionine, which contains Selenium atoms. A MAD experiment can then be
conducted around the absorption edge, which should then yield the position of
any methionine residues within the protein, providing initial phases.
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Heavy atom methods (i.e., MIR) – If electron-dense metal atoms can be
introduced into the crystal, direct methods or Patterson-space methods can be
used to determine their location and to obtain initial phases. Typically, heavy
atoms may be introduced either by soaking the crystal in a heavy atom-containing
solution, or by co-crystallization (growing the crystals in the presence of a heavy
atom). As in MAD phasing, the changes in the scattering amplitudes can be
interpreted to yield the phases. Although this is the original method by which
protein crystal structures were solved, it has largely been superseded by MAD
phasing with selenomethionine.
In addition, for every reflection corresponding to a point q in the reciprocal space,
there is another reflection of equal intensity at the opposite point −q. This opposite
reflection is known as the Friedel pair of the original reflection. This symmetry results
from the mathematical fact that the density of electrons f(r) at a position r is always a real
number. As noted above, f(r) is the inverse transform of its Fourier transform F(q);
however, such an inverse transform is a complex number. To ensure that f(r) is real, the
Fourier transform F(q) must be such that the Friedel pairs F(−q) and F(q) are complex
conjugates of one another. Thus, F(−q) has the same magnitude as F(q)— that is, |F|(q) =
|F|(−q)—but they have the opposite phase, i.e., φ(q) = −φ(q):

The equality of their magnitudes ensures that the Friedel pairs have the same intensity
|F|2. This symmetry allows one to measure the full Fourier transform from only half the
reciprocal space. In crystals with significant symmetry, even more reflections may have
the same intensity. In such cases, even less of the reciprocal space may need to be
measured.
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Chapter 3: Structural Studies of the Dihydropteroate Synthase (DHPS)

Background
There are currently five known structures of DHPS: B. anthracis (Babaoglu et al.,
2004), E. coli (Achari et al., 1997), S. aureus (Hampele et al., 1997), M. tuberculosis
(Baca et al., 2000), and S. Pneumoniae (Levy et al., 2008) as well as the structure of the
S. cerevisiae DHPS (Lawrence et al., 2005) which is fused to an additional enzyme of the
folate pathway, 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK). The
DHPS enzyme is a classic (α/β)8 TIM barrel. Several structures of DHPS in complex with
6-hydroxymethyl-pterine-pyrophosphate (PtPP) and 6-hydroxymethyl-pterinmonophosphate (PtP) have been reported (Hampele et al., 1997; Baca et al., 2000;
Babaoglu et al., 2004; Levy et al., 2008) and the pterin binding site is well characterized
(Figure 3.1A,B). In addition, the structure of DHPS complexed with pteroic acid, a
product analog, has been reported (Babaoglu et al., 2004) which revealed for the first
time the position of the pABA binding site (Figure 3.1C). These structures build a
preliminary model of the DHPS active site in which pterin binds into a highly conserved,
rigid pocket buried deep within the DHPS enzyme (Figure 3.1D). In contrast, pABA
binds to a surface region of the enzyme composed mainly of flexible loop regions which
stabilize upon substrate binding to complete the active site. Based on the PtPP and PtP
structures, Baca et al proposed a SN2 transition-state shown in Figure 3.2. In addition, it
has been shown that substrate binding into the DHPS active site proceeds via an ordered
mechanism where pABA binding is dependent upon the presence of bound DHPPP
(Babaoglu et al., 2004; Levy et al., 2008). Levy et al. demonstrated that pyrophosphate
was efficient to facilitate pABA binding in the absence of a pterin moiety correlating to a
SN2 mechanism.
These structural studies show that the DHPS active site is divided into two
separate, distinct regions: the pABA binding site and the pterin binding site. The pterin
binding site is a highly conserved pocket embedded within the core of the DHPS
structure and is composed of four key interactions with surrounding residues (Figure
3.1A,B,C): Arg254 pi-stacking interactions, Asn120 H-acceptor, Asp184 H-acceptor, and
Lys220 H-donor. Upon pterin binding, Lys220 extends to form a platform for pABA to
bind as indicated in the pteroic acid structure (Figure 3.1C). pABA is also stabilized in
the active site by an H-bonding interaction with Ser221. In addition, Levy et al.
demonstrated that Loops-1 and -2 fold in upon pterin binding to complete the pABA
binding site. However, these loop interactions have yet to be structurally characterized.
Since the pterin binding pocket is highly conserved (Figure 3.3), it seems logical that it
would be more difficult for the enzyme to accommodate mutations against pterin-based
compounds. In addition, mutations that could potentially cause resistance to pterin-based
inhibitors are likely to disrupt structural integrity since the pterin binding site is buried
within the protein. In contrast, the pABA binding site involves flexible loop regions near
the surface of the protein, and the rapid emergence of multiple sulfonamide resistance
mutations clearly show that they are easily tolerated within the overall structure of the

10
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Figure 3.1: Structure of the DHPS Active Site. A. DHPS active site with bound PtP
(PDB: 1EYE). Red arrow shows the direction of nucleophilic attack proposed by Baca et
al. and the green arrow represents the direction of nucleophilic attack indicated by the
pteroic acid structure. B. DHPS active site with bound PtPP (PDB: 1TWS). C. DHPS
active site with bound pteroic acid. Compound source of structure: Babaoglu, K., Qi, J.,
Lee, R.E. and White, S.W. (2004). Crystal structure of 7,8-dihydropteroate synthase from
Bacillus anthracis : mechanism and novel inhibitor design. Structure, 12 :1705-1717. D.
Surface representation of DHPS active site with bound pteroic acid indicating the
separate binding pockets for each substrate. Note that the pterin moiety is deeply
imbedded within the protein structure.

Figure 3.2: Schematic Representation of the DHPS Transition State.
11

Figure 3.3: DHPS Sequence Alignment. The ― ‖ means that the residues in that column
are identical in all sequences in the alignment. The ―:‖ means that conserved substitutions
have been observed. The ―.‖ means that semi-conserved substitutions have been
observed. Residues known to interact with pterin moiety are in red.
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protein. It is a long term goal of this project to develop new inhibitors of DHPS which
target the pterin binding site.
Results
While much of the DHPS active site has been structurally elucidated, key
interactions involving Loops-1 and -2 have yet to be determined. Therefore, it is the
purposes of this study to construct a more desirable model by which to study these loop
interactions. Analysis of the wild type B. anthracis structure revealed crystal packing
interactions involving Loops-1 and -2. As shown in Figure 3.4, Loop-1 is engaged in an
intramolecular packing interaction involving Phe33. Based on the M. tuberculosis
structure (Baca et al., 2000), Loop-1 is a central component of the active site, and any
movement of the loop would most likely destroy the crystals. Also, Phe33 has been
shown to be a resistance mutation in drug resistant strains of N. meningitides and E. coli
(Table 1.2). Loop-2, on the other hand, is folded into the pterin biding pocket forming πstacking interactions with Arg254 (Figure 3.5). These interactions bind the loops into
artificial conformations which prevent them from folding into the active site and, thereby,
hindering a functional conformation of these loops in structural studies. Several residues
located on Loop-2 have been shown to be involved in resistance mutations as well (Table
1.2). For these reasons, we have used site-directed mutagenesis techniques on surface
residues to break crystal packing interactions in an attempt to grow a different crystal
form in which these loops are free to interact with substrates upon binding. Analysis of
the crystal lattice led to the following mutations: Tyr39His and His137Glu (Figure 3.6).
These mutations were made based on the Y. pestis sequence. Furthermore, biochemical
studies using the radio-labeled assay (Materials and Methods) showed no significant
change in catalytic activity (data not shown).
After several crystal trials, crystals were found in a 1.5M sodium malonate pH =
5.00 condition (Figure 3.7A). The outward appearances of these crystals were strikingly
different from the wild type crystals grown by Babaoglu which were grown in a 1.3 M
Li2SO4, 0.1 M Bis-Tris propane, pH 9.0 condition (Figure 3.7B) indicating that the
mutations were successful in yielding an alternative crystal packing arrangement.
Crystals of the DM construct were grown in space group P212121 with unit cell
dimensions a = 100.3 Å, b = 107.9 Ǻ, c = 243.4 Ǻ, and the structure was solved to 2.0 Å
resolution by molecular replacement using the wild type B. anthracis structure as a search
model. Superposition of the double mutant structure showed no major conformational
changes in the protein architecture (data not shown).
Presented here is the crystal structure of the double mutant (DM) B. anthracis
DHPS (Figure 3.8). Analysis of the structures using PROCHECK (Laskowski et al.,
1993) showed that each has excellent stereochemistry and final R-factors that are
appropriate for their resolutions. Structure statistics are shown in Table 3.1. These
structures are comparable to the native DHPS structures preciously determined. There are
no significant differences apart from the conformation of loops and residues which
compose the actives site regions. There is no electron density for the N-terminal
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Figure 3.4: Crystal Packing Interactions Involving Loop-1.
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A

B

Figure 3.5: Crystal Packing Interactions Involving Loop-2. A. This structure shows pterin binding into the pterin-pocket. B. This
structure shows Arg68 binding into the pterin-pocket. Compound source of structure: Babaoglu, K., Qi, J., Lee, R.E. and White, S.W.
(2004). Crystal structure of 7,8-dihydropteroate synthase from Bacillus anthracis : mechanism and novel inhibitor design. Structure,
12 :1705-1717.
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A

B

Figure 3.7: Crystals of the B. anthracis DHPS. A. Crystals of the double mutant
construct. B. Crystals of WT B. anthracis.

A

B
Gly188
Thr67

Arg68
S. aureus
DM B. anthracis
M. tuberculosis

Pro69

Figure 3.8: Active Site with Functional Conformation of Loop-2. A. This view shows
stabilized Loop-2 with Arg68 directed towards the pABA binding site. Residues in green
are involved in drug resistance. B. This view shows the DM Loop-2 (orange) with pteroic
acid product analogue modeled in to the active site as well Loop-2 conformation from S.
aureus (yellow) and Loop-1 conformation from M. tuberculosis (purple).
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Table 3.1: Crystallization Data of the DHPS Double Mutant Construct.
Data Collection
Space Group
Cell Dimensions
a,b,c (Å)
α,β,γ (°)
Resolution (Å)
Rsym or Rmerge
I/ σI
Completeness (%)
Redundancy
Refinement Resolution (Å)
No. Reflections
Rwork/ Rfree
No. Atoms
Protein
Ligand/ Ion
Water
Ramachandran Plot
Most favored (%)
Additional allowed (%)
Generously allowed (%)
Disallowed (%)
R.M.S. deviation
Bond lengths (Å)
Bond angles (°)

DM Construct
P212121
100.357, 107.999, 243.443
90,90,90
50-2.4
9.3 (65.6)
12.2 (1.5)
98.4 (87.0)
6.7 (3.1)
50-2.6
113375
20.1/ 25.6
15912
120
784
88.4
10.6
0.5
0.5
0.010
1.500

Note: Values in parenthesis correlate to the highest resolution shell.
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methionine, the N-terminal 6xHis tag, or the final three C-terminal residues in any of the
structures.
The overall fold of the B. anthracis DHPS has been described in previous works
(Babaoglu et al., 2004). The basic fold of the protein is a classic (β/α)8 TIM barrel
(Banner et al., 1975) in which repeating β/α units create an eight-stranded parallel βbarrel surrounded by eight α-helices. In TIM barrel enzymes, the active site is located at
the C-terminal pole of the β-barrel and completed by interactions with surrounding,
flexible loop regions. The same is true for DHPS, however, there is some debate as to the
correct functional conformation of these loops as significant variations in conformation
have been reported in the various orthologs.
Loop-1 (residues 29-37) is highly conserved, but is not fully visible in any of the
eight monomers in the double mutant structure. Although it is highly conserved, its
conformation is reportedly highly variable which indicates that Loop-1 is a highly mobile
region of the DHPS active site. This would explain why Loop-1 is not visible in our
structure as well as monomer B of the WT B. anthracis structure and one monomer of the
S. aureus structure.
Loop-2 (residues 63-64) is also a highly conserved loop in the DHPS structure
and is visible in three of the eight monomers of the asymmetric unit. It adopts a bent
conformation (Figure 3.8A) in which R68 points towards the binding position of the
carboxyl group of pABA. We believe that this conformation of Loop-2 is of functional
significance and aids in stabilizing pABA in the active site.
By modeling in the pteroic acid structure from the wild type B. anthracis complex
(Babaouglu et al., 2000), we can visualize how this Loop-2 conformation may interact
with the carboxylic acid of pABA. Furthermore, modeling in the various loop
conformations from the M. tuberculosis and S. aureus structures sheds light on how these
loops are able to move and assist one another to facilitate substrate binding (Figure 3.8B).
The double mutant construct also yields several implications into the mechanism
of drug resistance. Specifically, the structure reveals the position of four key resistance
mutation sites. First, it shows the position of Thr67 located on Loop-2 which is mutated
to an Alanine in P. carinii and M. leprea mutant alleles (Figure 3.8A; Table 1.2). Second,
the structure reveals the position of Pro69 also on Loop-2 (Figure 3.8A) which is mutated
to a Serine in P. carinii and E. coli mutant alleles (Table 1.2) as well as the position of
Arg68 on Loop-2. Furthermore, the apparent flexibility of Loop-2 suggests that Pro69
and Thr67 function to structurally stabilize Loop-2 in order to direct Arg68 towards the
active site. Finally, the structure reveals the location Gly188 on Loop-6. Gly188 is
mutated to Cysteine in N. meningitides drug resistant alleles (Table 1.2). The position of
Gly188 suggests that the Gly188Cys mutation may function by sterically hindering the
binding of sulfamethoxazole into the DHPS active site.
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Chapter 4: Kinetic Studies of DHPS

Background
Current structural studies (see Chapter 3) build a preliminary model of the DHPS
active site in which pterin binds into a highly conserved, rigid pocket buried deep within
the DHPS enzyme. In contrast, pABA binds to a surface region of the enzyme composed
mainly of flexible loop regions which stabilize upon substrate binding to complete the
active site. Based on the PtPP and PtP structures, Baca et al proposed a SN2 transitionstate. In addition, it has been shown that substrate binding into the DHPS active site
proceeds via an ordered mechanism where pABA binding is dependent upon the presence
of bound DHPPP (Babaoglu et al., 2004; Levy et al., 2008). Levy et al. demonstrated that
pyrophosphate was efficient to facilitate pABA binding in the absence of a pterin moiety
correlating to a SN2 mechanism. However, the pABA binding site predicted in the
pteroic acid structure seemingly contradicts the SN2 mechanism as the direction of the
nucleophilic attack is not optimal.
Understanding the mechanism of DHPS catalysis is particularly important for
understanding the mode of sulfonamide resistance since sulfonamides inhibit the function
of DHPS by competing with pABA for active site binding (Brown, 1962). However, in
many instances these compounds undergo catalytic activity to produce sulfa-pterin
adducts (Roland et al., 1979; Patel et al., 2004; Valderas et al., 2008) which have been
implicated as inhibitors of dihydrofolate reductase (DHFR) (Patel et al., 2004). DHFR is
an enzyme downstream of DHPS in the folate pathway and is the target for several
inhibitors commonly used in synergism with sulfonamides. Historically, sulfonamides
have been used as first line treatments for several infectious diseases including malaria,
leprosy, pneumonia, E. coli, and S. aureus. However, drug resistance has emerged as an
important factor that severely limits the clinical use of sulfonamides (Sköld, 2000; 2001),
and resistance mutations in clinical isolates of many pathogenic organisms have been
characterized. The majority of these mutations are localized in Loops-1 and -2 which fold
in upon substrate binding to complete the pABA/sulfonamide binding site. For this
purpose, we have developed a radiometric assay to understand the involvement of Loops1 and -2 in the development of sulfonamide resistance.
Results
We have developed two assays to be used for kinetic studies, ELIPA (enzyme
linked inorganic phosphate assay) and a radio-labeled assay. In the ELIPA,
pyrophosphate released during the condensation of DHPPP and pABA is broken down
into inorganic phosphate by a pyrophosphatase. The inorganic phosphate then reacts with
2-amino-6-mercapto-7-methylpurine riboside (MESG) to produce mercaptomethylpurine and ribose-1-phophate. Since the absorption ranges of MESG (330 nm) and
mercato-methylpurine (360 nm) are different, the amount of pyrophosphate released can
be measured by observing an increase in absorption at 360 nm over time. Therefore, the
20

results of the ELIPA experiment correlate to the amount of phosphate released during
catalysis. Two reactions were tested by this method: the reaction DHPPP + pABA and
the reaction of DHPPP + SMX (sulfamethoxazole) in the absence of pABA. As shown in
Figure 4.1, both reactions show a comparable release of phosphate indicating that SMX is
able to undergo enzymatic catalysis. While these results reveal a unique characteristic of
the sulfonamide class of drugs, they limit the use of the ELIPA experiment for studies in
antibiotic resistance. To overcome this issue, we developed a radio-labeled assay using
14
14
C pABA as one of the substrates and monitoring the appearance of C-labeled product
by thin-layer chromatography (Nopponpunth et al., 1999; Kasekarn et al., 2004).
The radiometric assay was used to measure the kinetic parameter Km and Kcat of
mutated DHPS enzymes. Several types of sulfonamide resistance determinants have been
identified (Sköld, 2000; 2001). Five point mutations were identified and chosen for this
study (P69S, T67A, R68A, G188C, and F33L) based on the relative position to either
Loop-1 or Loop-2. Each mutated strain was mutated from the WT strain of B. anthracis
using site-directed mutagenesis as described in Material and Methods. Mutations P69S,
T67A, R68A, and G188C all show an increase in Km and Kcat values as compared to the
WT enzyme indicating that the enzyme must lower efficacy to accommodate sulfonamide
resistance (Table 4.1). The mutation F33L showed no activity in vitro as compare to the
WT enzyme (Table 4.1; Figure 4.2). However, an extensive literature search yields
reports of clinical isolates with this specific mutation (Dallas et al., 1992; Fermer &
Swedberg, 1997). Furthermore, these isolates were obtained from sulfonamide resistance,
pathogenic strains (Dallas et al., 1992; Fermer & Swedberg, 1997; Lane et al., 1997).

pABA :
+ 32uM [DHPPP] + 30uM [pABA]
control : + 32uM [DHPPP]
SMX-50 : + 32uM [DHPPP] + 50uM [SMX]

Figure 4.1: Results from the ELIPA Experiment.
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Table 4.1: Kinetics Studies of Mutant Alleles.
SMX

SNA

Construct

Km (μM)

Kcat (min-1)

IC50 (μM)

Ki (μM)

IC50 (μM))

Ki (μM)

WT

0.3370 (± 0.1263)

21.82 (± 2.17)

2.258 (± 0.232)

0.143 (± 0.014)

18.52 (± 1.72)

1.169 (± 0.108)

P69S

5.751 (± 2.454)

7.000 (± 1.43)

5.196 (± 0.434)

2.779 (± 0.232)

39.88 (± 3.61)

21.33 (± 1.93)

T67A

0.5823 (± 0.200)

11.16 (± 1.02)

10.26 (± 0.95)

1.070 (± 0.099)

315.5 (± 72.0)

32.91 (± 7.50)

R68A

1.523 (± 0.719)

13.43 (± 2.31)

0.881 (± 0.064)

0.206 (± 0.015) 13.42 (± 1.406) 3.133 (± 0.328)

G188C

0.699 (± 0.250)

7.29 (± 0.83)

7.1754 (± 1.653)

0.880 (± 0.203)

31.24 (± 5.96)

3.831 (± 0.731)

F33L

> 50

N/A

N/A

N/A

N/A

N/A
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F33L
DHPS

WT
DHPS

14

C pABA

14

14

C pABA

C product

Figure 4.2: Results from the Radiometric Assay.
In order to understand our results, we verified that the mutation was successful.
To do so, we isolated the plasmid of interest and sequenced the gene by the dideoxy
chain-termination method for sequencing DNA. These results were then aligned with the
wild type sequence and analyzed for the appearance of mutations. As seen in Figure 4.3,
the alignment revealed that the triad TTT encoding for Phenylalanine 33 was indeed
mutated to a CTG encoding for a Leucine. Therefore, the mutation was correct and the
results observed in the radiometric assay correlate to a F33L mutation.
In addition to Km and Kcat studies, IC50 values in the presence of sulfamethoxazole
(SMX) were determined for each mutant enzyme as well as IC50 values in the presence
sulfanilamide (SNA). Mutations P69S, T67A, R68A, and G188C all showed an increase
in IC50 values as compared to WT in the presence of both SMX and SNA (Table 4.1).
However, the ability was amplified against SNA as compared to SMX indicating that the
terminal ring of SMX may be hindering the enzyme’s ability to develop drug resistance
while maintaining a viable enzyme. This data showed that the T67A mutation has the
most pronounced effect upon developing drug resistance while having the least effect on
the catalytic efficacy of the enzyme. In contrast, R68A and P69S mutations seem to offer
little sulfonamide resistance in light of a five fold or better loss in the catalytic efficacy.
These results yield a great deal of insight into the catalytic mechanism of the enzyme as
well as key residues necessary for catalysis, namely P69, R68, and F33 all of which are
highly conserved residues in the DHPS sequence.
In addition to the kinetic studies, we have performed preliminary structural
studies of the mutant alleles. We have successfully crystallized P69S, F33L, and T67A
mutants (Figure 4.4), but we have not been able to visualize Loops-1 or -2 in these crystal
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Figure 4.3: F33L Sequence Verification.
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P69S

T67A

F33L

Figure 4.4: Crystallization of the P69S, T67A, and F33L Mutant Alleles.
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structures. Attempts have been made to co-crystallize these mutant enzymes with pteroic
acid, but with no success to date.
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Chapter 5: Discussion

The Conformation and Roles of Loops-1 and -2
In all known crystal structure of DHPS, including the double mutant construct
reported in this thesis, Loops-1 and -2 adopt highly variable conformations or are missing
all together. This observation suggests that these loops are highly mobile and work in an
ordered manner to aid in substrate binding and stabilization. As regards to Loop-1, we
can offer no new structural insights into the why it is so conserved. Based on the M.
tuberculosis structure, Loop-1 can fold in such a way as to allow key residues such as
Asp35 to interact with the pABA binding sight. Our kinetics data reiterates the
importance of Loop-1 for pABA binding by revealing that Phe33 is essential to the
catalytic efficacy of the enzyme.
The conformation of Loop-2 that we present in the DHPS double mutant construct
is unique amongst the known DHPS structures. By modeling in the pteroic acid product
analogue, our structure reveals that the side chain of conserved Arg68 bends towards the
carboxylic acid component of pABA to stabilize it in the binding site. Babaoglu et al.
reports that Arg68 folds into the pterin binding sight to give added stability to the
unliganded enzyme. This report in conjunction with our data suggests that Arg68 may
function to ensure pABA can only bind if the pterin substrate is already bound into the
active sight. The suggested binding of pABA between ordered Loops-1 and -2 would
essentially block the pterin pocket, thereby preventing pterin from binding into the active
site. This is further confirmed by previous reports that enzyme catalysis proceeds via an
ordered mechanism in which bound pterin is required for pABA binding (Vinnicombe &
Derrick, 1999; Levy et al., 2008). Our structure shows for the first time a functionally
significant conformation of Loop-2 and the role of Arg68 in enzyme catalysis.
Implications of Sulfonamide Resistance
Antibiotic resistance is the ability of a microorganism to overcome the effects of a
particular drug due to genome modifications. This process occurs via natural selection in
which random point mutations lead to natural selection of a drug resistant gene. Such
genes can then be inserted in to the pathogen genome via horizontal gene transfer (Ochiai
et al., 1959). Introduction of antibiotic action against a pathogen creates an
environmental stress in the system. Bacteria which have the mutation allowing them to
survive will reproduce ensuring that the advantageous gene mutation is passed on to their
offspring (Figure 5.1). The result is a fully resistant colony.
Microorganisms are able to exhibit antibiotic resistance in a variety of ways. The
four most common modes of resistance development are as follows: drug inactivation or
modification, alteration of target site, alteration of metabolic pathway, and reduced drug
accumulation.
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Initial Population

Exposure to Environmental Stress
(Antibiotic)

Final Population

Resistance Level

Figure 5.1: Schematic Representation of the Formation of Antibiotic Resistant Colonies.

28

This study clearly shows that specific point mutations in the target site of
sulfonamide binding leads to a decrease in binding affinity of sulfonamides. Specifically,
mutations which disrupt the structural stability of Loops-1 and -2 have significant effects
on drug binding which ultimately lead to antibiotic resistant bacterial strains. This
evidence suggests that these flexible loop regions of the DHPS enzyme can readily
accommodate point mutations while maintaining a functionally viable enzyme.
Therefore, it is important to avoid such regions during the development of novel
therapeutics which target the DHPS enzyme.
The Catalytic Mechanism of DHPS
By docking in the pteroic acid structure into our new DHPS structure with a
functionally significant conformation of Loop-2, it is possible to generate a model of the
DHPS catalytic mechanism (Figure 3.8). This model shows that SMX binds to the DHPS
active site in a similar fashion as pABA and this interaction is facilitated by Arg68 as
well as additional components of Loop-2. Furthermore, the position of SMX in the active
site reiterates the proposed SN2 mechanism previously reported by Babaouglu and
colleagues.
Based on previous data in conjunction with the data presented in this thesis, we
propose that the mechanism proceeds by four steps via an ordered mechanism. In the
initial state, Arg68 is bound into the pterin pocket as seen by Babaouglu and colleagues.
During the first step, DHPP binds into the active site (Vinnicombe & Derrick, 1999; Levy
et al., 2008) displacing Arg68 from the pterin pocket. This causes a conformational shift
of Loop-2 which can easily be envisaged by comparing our new Loop-2 conformation
with those of previously reported conformations in the E. coli and S. aureus structures.
Facilitated by the pterin moiety, the β-phosphate enters the anion binding pocket and the
divalent cation binding site involving Asn27 from Loop-1 becomes occupied by the
Mg2+ ion that coordinates the pyrophosphate for an SN2 reaction. Indeed, the divalent
cation may aid in drawing Loop-1 into the active site and thereby bringing Phe33 with it.
The second step creates the pABA binding site. Formation of the pABA binding site is
facilitated by the binding of the DHPP and the binding of Lys220 to the pterin moiety.
Lys220 stretches to form a platform by which pABA can dock into the active site. As
Lys220 swings out it exposes the N-terminal end of helix α-Loop-7 for additional
hydrogen binding interactions. The pABA binding site is completed by movement in
Loops-1 and -2, and Arg68 in its new conformation seen in the Pt-SMX structure now
interacts with pABA via charge interactions and π-stacking interactions. The third step
involves nucleophilic SN2 attack by the nitrogen group of pABA on the methyl carbon
on the C6 position of DHPP. The divalent ion coordinates the pyrophosphate and
functions to make it a better leaving group facilitating an SN2 attack. During the final
step, Loop-2 reinserts into the pterin pocket and product is released for further
modification down the metabolic pathway. The enzyme is then ready to repeat the
enzymatic mechanism with new substrate. Table 5.1 depicts all the residues believed to
be involved in the catalytic mechanisms as well as synonymous residues in different
organisms. The residues colored red represent those with sequence variance as compared
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Table 5.1: Sidechains Involved in Substrate Binding.
B. anthracis
Thr67
Arg68
Asp101
Asn120
Ile122
Ile143
Met145
Asp184
Phe189
Leu214
Gly216
Lys220
Arg254

Interaction Type
H-donor/ Pi Electronics
H-acceptor
vDW
vDW
Pi Electronic
H-acceptor
Pi Electronic
vDW
H-donor
Pi Electronic

E. coli
Thr62
Arg63
Asp96
Asn115
Ile117
Cys137
Met139
Asp185
Phe190
Leu215
Gly217
Lys221
Arg255

S. aureus
Thr51
Arg52
Asp84
Asn103
Gln105
Val126
Met128
Asp167
Phe172
Leu197
Ala199
Lys203
Arg239

Note: Residues in red are those that diverge from the B. anthracis sequence
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M. tuberculosis
Ser53
Arg54
Asp86
Asn105
Val107
Val128
Met130
Asp177
Phe182
Leu207
Gly209
Lys213
Arg253

S. pneumoniae
Thr57
Arg58
Asp91
Asn110
Ile112
Val133
Met135
Asp201
Phe206
Phe231
Gly233
Lys237
Arg282

P. aeruginosa
Ser49
His50
Asp82
Asn101
Ile103
Val123
Met125
Asp173
Phe178
Leu206
Ser208
Lys212
Arg246

to the B. anthracis sequence. In addition, the table shows the types of interactions each
residue participates in upon substrate binding.
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Chapter 6: Materials and Methods

Cloning of the folP Gene
The anthrax folP gene encoding DHPS was obtained by PCR amplification using
genomic DNA obtained from the Sterne 34F2 strain of Bacillus anthracis as described in
Babaouglu et al., 2004. The following primers, with inserted restriction sites in italics,
were designed using the sequence from the A2102 strain deposited in the NCBI database
(gi:21397375): 5’ NdeI: CATATGAAGTGGGATTATGATTTGCGC and 3’ BamHI:
GGATCCTTACTTTACCCCTTACCAATCATCGC.
Three reactions were set up using the High Fidelity supermix kit (Invetrogen,
Carisbad, CA) and the protocol suggested in the product literature. The PCR reaction
consisted of an additional heating step for 2 min. at 94°C followed by 25 cycles of 30 sec.
at 94°C, annealing at 53°C for 30 sec., and extension at 72°C for 2 min. The PCR
products were analyzed on a 1% agarose gel stained with ethidium bromide to identify
the amplification species of the appropriate size (846 bp). The PCR products were
purified, subcloned using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA) into the
pCR 2.1 TOPO vector, and finally sequenced to ensure that the restriction during the
PCR reactions. Primer synthesis and DNA sequencing were performed by the Hartwell
Center at St. Jude Children’s Research Hospital.
Protein Expression and Purification
The folP gene encoding DHPS was obtained and subcloned from the TOPO TA
vector into the pET-28a expression plasmid (Novagen, Madison, WI) that incorporates a
6xHis Tag at the N terminus of the expressed protein (Babaoglu et al., 2000). Two
surface residues were mutated using Quickchange® (Stratagene, La Jolla, CA) sitedirected mutagenesis. The plasmid was then transformed into competent BL21 (DE3) E.
coli cells (Stratagene) for expression. A 100mL overnight culture was grown form a
single colony of cells in LB containing 50 μg/ml kanamycin, and this culture was used to
inoculate 6 L. of the same medium. This was grown at 37°C until the OD600 reached ~0.6,
at which point isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final
concentration of 1 mM. Cell were then allowed to grow overnight at 16°C in the presence
of IPTG and then harvested by centrifugation. The cell pellet was resuspended in 50 ml
lysis buffer (20 mM NaPO4, pH 8.0, 0.5 mM NaCl, and 1mM Imidazole). The cells were
lysed by a microfluidizer, and the cell debris was cleared by centrifugation at 30,000 x g
for 1 hour.
Purification of DHPS required two steps of Fast Performance Liquid
Chromoatography (FPLC), Ni2+ chelation affinity chromatography and gel filtration.
The cell lysate was first applied to a 5 ml HiTrap Chelating HP column (Amersham
Biosciences, Piscataway, NJ) and washed with ten column volumes of lysis buffer. The
protein eluted during a gradient of 0-0.3 M imidazole, and the appropriate fractions were
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identified by SDS-PAGE. The pooled DHPS was concentrated to 3 ml, applied to a
HiLoad 16/60 Superdex 75 column (Amersham Biosciences), and eluted with running
buffer (20 mM NaPO4, pH 8.0, 0.2 M NaCl, 1 mM dithiothreitol (DTT), and 1 mM
MgCl2) at a flow rate of 0.5 ml/min. The final purified protein was estimated to be >95%
pure by SDS-PAGE analysis.
Crystallization and Data Collection
The purified enzyme was concentrated with an Amicon stirred cell to a final
concentration of 10 mg/ml. Using the hanging drop vapor diffusion method together with
Hampton Crystal Screens kits (Aliso Viejo, CA), a number of initial crystallization
conditions were identified by mixing equal volumes (2 μl) of protein to well solution.
These conditions were subsequently optimized, and large well-diffracting crystals could
eventually be grown from 1.8 M Sodium Malonate. Large rectangular box shaped
crystals could be obtained within 72 hrs at 18°C. The crystals are in space group P212121
with cell dimensions a = 100.357 Å, b = 107.999 Å, c = 243.443 Å. Consideration of the
Mathews coefficient suggested that eight molecules of DHPS should be present in the
asymmetric unit, and this was subsequently confirmed. For the structural studies of
pterin-sulfamethoxazole (Pt-SMX), the compounds were directly added to pregrown
crystals in the form of saturated solution in the crystallization buffer, and allowed to soak
for 72 hrs.
All x-ray diffraction data were collected under cryogenic conditions. Crystals
were briefly immersed in a cryoprotectant mixture of 25% glycerol and directly flash
frozen in liquid nitrogen. All data were collected at the Southeast Regional Collaborative
Access Team (SER-CAT) synchrotron beamline 22-ID and 22-BM at the Advanced
Photon Source (Argonne National Laboratory). All crystals were frozen and prescreened
in-house before synchrotron data collection. The DHPS-PtSMX synchrotron data were
collected on a MAR300 CCD detector and processed and merged using HKL2000
(Otwinowski & Minor, 1997). All relevant data collection statistics are shown in Table
3.2.
Structure Determination
The structure of the double mutant DHPS from B. anthracis was determined by
molecular replacement using the CCP4 program Phaser (McCoy et al., 2007). Monomer
A of the wild-type B. anthracis structure (PDB: 1TWS) was used as an initial search
model. A solution was obtained using high resolution synchrotron data and refined
following several iterative rounds of rebuilding in COOT (Emsley & Cowtan, 2004), and
simulated annealing and temperature factor refinement using CNS (Brüger et al., 1998).
All the waters were picked automatically using COOT and subsequently confirmed by
visual inspection. Finally, to verify ambiguous regions of the electron density and to
check the model, a number of simulated annealing omit maps were calculated during the
later stages of the refinement process. The quality of the structure was verified using
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PROCHECK (Laskowski et al., 1993), and the final refinement statistics are shown in
Table 3.1.
Radiometric Assay
14

To observe enzyme kinetics, we developed a radio-labeled assay using C pABA
14
as one of the substrates and monitoring the appearance of C-labeled product by thinlayer chromatography (Nopponpunth et al., 1999; Kasekarn et al., 2004). For the first
reaction (synthesis of DHPPP), the substrate (10 μM of HMDP) was incubated in
o
presence of ATP (250 μM), MgCl2 (10 mM), and HPPK enzyme (10 μg) at 37 C for 30
minutes. The reaction solution was mixed with GST resin, and the supernatant was
collected for the second step of the reaction. DHPS activity was measured in a 50 μL
reaction containing 50 mM HEPES (pH 7.6), 10 mM Mg Cl2, 1% PEG 400, and 2%
14
DMSO. For Kcat and Km determination, varying concentrations of DHPS, 0-3 μM C
pABA, and 10 μM DHPPP from the first reaction were added to the reaction mixture. For
14
Ki and IC50 determination, varying amounts of DHPS, 5 μM C pABA, 10 μM DHPPP
and 0-50 μM of SMX were added to the reaction mixture. The reaction solution was
o
incubated at 37 C for 30 minutes. The labeled product of the enzymatic reaction was
separated from the labeled pABA by thin layer chromatography. 25 μL aliquots of the
reaction mixture were spotted onto PEI-cellulose coated plates and developed with
ascending chromatography in 100 mM phosphate buffer, pH 7.4. With this method, we
are able to perform Michealis-Menten kinetics for wild type and mutant enzyme activity
as well as determine the IC50 values of candidate inhibitors. Since sulfonamides are
competitive inhibitors of DHPS, Ki values were determined using the Cheng-Pursoff
equation and represent the amount of inhibitor that will bind to half the enzyme active
sites at equilibrium in the absence of substrate (Cheng & Prusoff, 1973). Enzyme kinetics
data were determined by nonlinear regression using the Graphpad Prism4 software.
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Chapter 7: Future Directions and Conclusions

Developing a Robust Enzyme Assay
While our current assays are effective for interpreting changes in KM which occur
as a result of sulfonamide-resistance mutations, the formation of sulfonamide products
makes IC50 and Ki values difficult to interpret as DHPPP depletion may alter inhibition in
a way that does not correlate physiologically. Therefore, a more robust method for
studying sulfonamide inhibition is essential for understanding the mode of enzyme
resistance. To overcome these issues, we propose the use of stopped-flow transient
kinetics.
Stopped-flow fluorescence spectroscopy is a useful tool for determining the
dissociation constant (Kd) for individual substrates. This method is particularly useful in
systems, such as the DHPS system, with intrinsically fluorescent substrates. Changes in
the fluorescence of the pterin ring as well as pABA have been used to measure binding of
substrates in both wild-type and sulfonamide resistant enzymes (Levy et al., 2008). We
will use similar methods as described in Levi et al. to fully characterize the effects of
sulfonamide resistance mutations on substrate and inhibitor binding. In addition,
fluorescence probes can be used to understand conformational shifts which occur in loop
regions of DHPS to facilitate substrate binding. Intrinsic Tryptophan fluorescence is
responsible for the majority of fluorescence observed in proteins. A sequence analysis of
the wild-type B. anthracis DHPS revealed only two Tryptophan residues which are far
removed from the enzyme active site. Since neither residue is conserved, it stands to
reason that they can easily be mutated out with no consequence to enzyme integrity. This
frees the enzyme of unwanted fluorescence and allows the use of Tryptophan as a
fluorescence probe. We will use site-directed mutagenesis to place Tryptophan residues
in strategic regions of the enzyme to better understand the role of Loops-1 and -2 and
their involvement in substrate binding.
While it has been shown that pyrophosphate is essential for pABA binding (Levy
et al., 2008), it has yet to be shown whether or not pyrophosphate is required for catalytic
function. This is critical for understanding the catalytic mechanism as the presence or
absence of pyrophosphate is directly linked to the nature of the transition-state
intermediate. In the event of an SN1 reaction, pyrophosphate is released to form a
carbocation intermediate prior to attack by pABA. However, pyrophosphate is required
for the formation of the SN2 transition-state intermediate as proposed by Baca et al. and
release of pyrophosphate in the absence of a nucleophilic attack can only occur as a result
of an SN1 mechanism. Therefore, we will use inactive substrates which mimic pABA,
such as benzoic acid, and monitor the release of pyrophosphate using our enzyme linked
inorganic phosphate assay (ELIPA). This approach will provide direct evidence as to the
nature of the enzyme transition-state as well as a model for understanding the catalytic
mechanism.
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In the ELIPA, pyrophosphate released during the condensation of DHPPP and
pABA is broken down into inorganic phosphate by a pyrophosphatase. The inorganic
phosphate then reacts with 2-amino-6-mercapto-7-methylpurine riboside (MESG) to
produce mercapto-methylpurine and ribose-1-phophate. Since the absorption ranges of
MESG (330 nm) and mercato-methylpurine (360 nm) are different, the amount of
pyrophosphate released can be measured by observing an increase in absorption at 360
nm over time.
In addition to our in vitro assays, we will use a DHPS knockout strain (JW3-1441; Baba et al., 2006) of E. coli to determine the minimal inhibitory concentration (MIC)
of sulfonamides as a means of analyzing the effects of sulfonamide resistance mutations
on bacterial growth. Using the pBAD/His (Invitrogen) plasmid system, we will insert our
DHPS gene of choice into the knockout cells. The pBAD/His system is advantageous
because it provides a low copy system (pBR322 origin) with a leaky promotor (araC
ORF) which will allow for approximate basal level expression of DHPS and DHPS
mutant enzymes with no additional stimuli required. Two positive controls will be
required for this experiment. First, transformation of the DHPS knockout strain with
wild-type DHPS will provide a baseline for comparing MICs. Second, a DHPS positive
strain of E. coli will be used to determine wild-type MICs which may be altered in our
plasmid system due to over expression of the plasmid inserts. A negative control will also
be provided in which the DHPS knockout strain will be transformed with an empty
plasmid. It should be noted that DHPS knockout strains of E. coli will require folate
supplements. However, once the DHPS plasmid is transformed into the system
supplements will be removed from the media and should not effect MIC determination.
This is a widely used technique for understanding drug resistance (Rock et al., 2003;
Zhang et al., 2004)) and will provide a more accurate method for evaluating the effects of
drug resistance.
Probing the Enzyme Mechanism
With the introduction of kits like Quickchange® (Stratagene), site-directed
mutagenesis has become a relatively straightforward method for designing point
mutations. This technique will be of great importance for the advancement of this project
as it will allow us to probe the enzyme active site for catalytically significant residues.
Several residues have already been identified and will be mutated in ways as to both
diminish and enhance catalytic activity according to predicted function. For instance,
Asparagine 27 (B. anthracis) is predicted to coordinate the divalent cation which is
predicted to protonate the pyrophosphate leaving group. Therefore, mutating Asparagine
27 to an Alanine should diminish catalytic activity of the enzyme where as mutation to a
Histidine should restore enzyme function.
The current understanding of the DHPS mechanism assumes an SN2 transition
state. However, conflicting data in the literature as to the direction of the nucleophilic
attack requires further investigation into the nature of the enzyme transition-state. To
distinguish between a SN2 and a SN1 mechanism, we have analyzed the enzyme active
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site to identify conserved residues which aid in transition-state stabilization. In order for
the reaction to proceed via SN1, the enzyme must have a way of stabilizing a carbocation
intermediate. Aspartate 35 (B. anthracis) is a highly conserved residue on Loop-1 and is
predicted to stabilize the formation of a carbocation by electrostatic interactions in the
event of a SN1 reaction. In contrast, it is a less crucial candidate for an SN2 transitionstate because there is no longer a positive charge on the pterin moiety to be neutralized.
Therefore, mutating Aspartate 35 to an Alanine or a lysine will provide critical
information pertaining to the nature of the enzyme transition state.
In addition, our preliminary data shows that Loop-2 folds into the active site upon
substrate binding. Furthermore, disruption of the rigidity of Loop-2 by mutating of
Proline 69 (B. anthracis) to a Serine diminishes catalytic activity by 3-fold. Evidence
suggests that Loop-2 is necessary to direct Arginine 68 (B. anthracis) into the active site
as mutation of Arginine 68 to an Alanine yields a 2-fold reduction in the rate of catalysis.
To further understand the role of Loop-2, we will perform a series of mutations using an
Alanine probe along Loop-2 as well as removal of Loop-2 to observe the effects on
catalysis using our radiometric assay. In conjunction with our radiometric assay, we will
determine effects of Loop-2 mutagenesis on pyrophosphate as well as pABA binding
utilizing fluorescence techniques described by Levy et al.
Fragment-Based Virtual Screening
Structural data suggests that the pABA and pterin binding sites are separate,
distinct regions in the DHPS molecule (Achari et al., 1997) allowing for the development
of inhibitors capable of inhibiting sulfonamide-resistant forms of DHPS. Since the pterin
binding pocket is highly conserved, it seems logical that it would be more difficult for the
enzyme to accommodate mutations against pterin-based compounds. In addition,
mutations that could potentially cause resistance to pterin-based inhibitors are likely to
disrupt structural integrity since the pterin binding site is buried within the protein. In
contrast, the pABA binding site involves flexible loop regions near the surface of the
protein, and the rapid emergence of multiple sulfonamide resistance mutations clearly
show that they are easily tolerated within the overall structure of the protein. By targeting
the pterin binding site, we hypothesize that we will be able to overcome the problems of
sulfonamide resistance which have arisen by mutations in the pABA binding site.
While we have successfully identified several target compounds, the majority of
these compounds have been pterin-like compounds which are often insoluble. To
overcome this issue, we will use fragment-based virtual screening to identify scaffold
compounds for lead optimization to produce highly efficient, drug-like inhibitors. The
general approach to this aim will be structure-based drug design techniques in which
virtual screening is used in synergism with structural and biochemical data.
Fragment-based drug discovery is a highly integrated process which begins with
the screening of fragment libraries and utilizes structural and biochemical techniques to
produce drug-like compounds. We will adopt a modified rule of three in which library
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searches are limited to compounds with a molecular weight less than 350 and no more
that 5 rotatable bonds. Pharmacophore constraints will be applied based on substrate
binding, but these will be limited to partial match derivatives to loosen the macro
constraints and allow for ligand diversity. The hit compounds will be docked and scored
using the methods described in preliminary data. Of the highest scoring compounds, the
top 1% will be moved to biochemical studies.
We will use our radio-labeled assay as our primary method for studying
inhibition. In contrast to the sulfonamides, these compounds will not be able to undergo
enzyme catalysis, and we predict that this method will be an acceptable assay for
inhibition kinetics. However, the ELIPA assay is available should an alternative be
required. Compounds with greater than 30% inhibition of the wild-type DHPS will be
moved into structural studies.
Visualization of these compounds is an essential step in our approach as it will
allow us to see how the fragment compounds bind into the pterin pocket. This is
advantageous for two reasons. First, it provides a model by which we can optimize these
fragments into lead compounds with drug-like properties. Second, it provides a validation
scheme for our docking and scoring functions. As a result of these studies, we will
identify several lead compounds as candidates for novel therapeutics to be used against a
wide variety of infectious agents.
Although we predict that the pterin pocket is less likely to accommodate
resistance mutations, we cannot deny that this is a possibility. Therefore, we will grow E.
coli cultures in agar containing varying amounts of drug concentration and observe for
growth. The DHPS gene (folP) from the genomic DNA of cultures found to grow in the
presence of drug will be PCR (polymerase chain reaction) amplified and sequenced to
determine the presence of drug resistance mutations. In a similar fashion, E. coli cultures
will also be used to determine the minimal inhibitory concentration (MIC) of these
compounds to evaluate their ability to pass through the membrane barrier. Analysis of
these compounds by these methods will allow us to evaluate and optimize chemical
characteristics of the compounds before moving into an animal model and ensure the
over all success of this project.
Expanding the Pool of Known DHPS Structures
With the assistance of the bioinformatics group at the Hartwell Center at St. Jude
(Dr. Perdeep Mehta), we identified the DHPS gene from the genomic sequence of F.
tularensis and discovered that it is fused with the gene for HPPK. Analysis of the
sequence revealed that the C-terminal helix of DHPS, a key component of the TIM
barrel, is missing. To ensure that the sequence is correct, we have obtained the genomic
DNA and resequenced the DHPS region. Our initial sequence is correct and the gene has
been PCR amplified and introduced into our standard pET28a expression vector, and
pure soluble protein is now available for crystallization trials (Figure 6.1). However,
biochemical data suggest that the DHPS component is inactive while the HPPK is active
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(data not shown). Further analysis into the cause of inactivity is necessary and will be a
priority in this project as it is likely to reveal crucial information regarding the enzyme
mechanism. Y. pestis genomic DNA was obtained from Dr. Brubaker (Michigan State
University), the gene was PCR amplified, expressed, and the purified protein is currently
undergoing crystallization trials (Figure 6.1). The Y. pestis gene is a standard bacterial
enzyme and is fully functional (data not shown).
We will use crystallographic methods to incorporate other infectious agents into our
inhibitor studies including those with already known structures (S. aureaus, M.
tuberculosis, etc.) as well as class A agents of biowarfare, F. tularensis and Y. pestis. The
structure determination of the F. tularensis and Y. pestis should be relatively
straightforward. Preliminary crystals have been observed and are in the process of
optimization. We anticipate that optimization of initial crystals will be successful.
However, alternative methods are available should quality crystals prove difficult to
obtain.
The reductive methylation of surface lysines has been shown to alter the crystal
formation of various proteins and is a straightforward and efficient way for improving
crystal quality (Rypniewski et al., 1993; Rayment, 1997; Kobayashi et al., 1999; Walter
et al., 2006). In hen egg white lysozyme, it was shown that the methylation of all six
lysine residues resulted in only minor changes in the overall protein architecture
(Rypniewski et al., 1993). While several reductive methylation methods have been
performed, we have chosen to employ formaldehyde as the alkylating reagent and
dimethylamine borane complex as the reducing agent since they have been shown to have
the mildest effects on the biochemical properties of the protein (Rayment, 1997).
Examination of the B. anthracis DHPS structure revealed that the majority of lysines
(8/20) present in the structure were surface residues. Based on sequence alignment, we
predict this to be true of the Y. pestis (9 lysines) and F. tularensis (41 lysines) DHPS.
Limited proteolysis as a second technique commonly used for obtaining quality
crystals and is a straightforward technique. Using a variety of proteases, flexible regions
of protein which may be involved in unfavorable interactions during crystallization can
be identified and removed (Dong et al., 2007). Information obtained through treatment

50 kDa
35 kDa

Ft
Ft

Yp

Figure 7.1: Purification Gels of Y. pestis and F. tularensis DHPS. Note that the F.
tularensis DHPS has a larger molecular weight due to fusion with HPPK.
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with proteases can then be used to form new protein constructs for crystallization trials.
This will be particularly useful with the F. tularensis construct as it may be necessary to
cleave the HPPK and the DHPS enzymes to produce diffraction quality crystals.
As mentioned above, the F. tularensis DHPS was found to be inactive. This is
unexpected as the active site residues are present in the sequence and align well with the
DHPS sequence of other organisms. One notable difference in the F. tularensis sequence
is the loss of the c-terminal helix which is an essential component of the TIM barrel. We
will use site-directed mutagenesis to reinstate this terminal helix and study the effects on
activity using the ELIPA. In addition, microbiology techniques will be used to determine
the effects of the F. tularensis DHPS in E. coli cells. This will yield one of two results.
First, E. coli cells are able to grow using the F. tularensis DHPS indicating that the
enzyme requires additional elements not present in our assay. Second, E. coli cells are
unable to grow indicating that the enzyme is nonfunctional. In the latter scenario, it will
be necessary to examine the genomic sequence of F. tularensis to determine the presence
of divergent orthologs which may explain this unusual result. Furthermore, Larrson et al.
has evaluated the genome sequence of F. tularensis and identified several holes in a
variety of metabolic pathways indicating that the bacterium is becoming increasingly
host-dependent. While they do not indicate any holes in the folate pathway based on
sequence analysis, this may explain the inactive form of DHPS. Examination of why this
enzyme is inactive remains an important aim for this project and will undoubtedly
provide crucial evidence into the enzymatic mechanism.
Conclusions
In an increasingly mobile and interconnected world, the transfer of infectious
disease has become a serious threat through out the entire world and given rise to a need
for novel therapeutics. The research proposed in this thesis gives a rational, valid method
for overcoming the problems posed by present antibiotics and a plan for developing
improved drug therapeutics.
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